The purpose of this study is to determine the effectiveness of a combined dermatological treatment in children up to 5 years old with mild or moderated atopic dermatitis.
The intensive cream and body lotion of the PediATOPIC® products are two emollients expressly formulated to serve as adjuvants in the management of Atopic Dermatitis. Both products contain Dermosense complex®, a complex that includes 3 products: Bodyfensine peptide® (inductor of dephensine synthesis against microbial aggressions), Unimoist® (the mimetizing complex of the skin's natural hydration factor), and Ramnosoft® (polysaccharide that inhibits the adhesion of pro-inflammatory drugs and bacteria, while limiting the spread of inflammatory reactions in skin cells). They also contain Bisabolol, (plant extract with anti-inflammatory, anti-irritant and antimicrobial properties) and Panthenol (Pro vitamin B5 that accelerates the skin's natural regeneration process).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
43
Applied twice a day minimum.
Applied at libitum.
Centre Medic Digest
Badalona, Barcelona, Spain
Centro médico Quirón Teknon
Barcelona, Spain
Changes in Atopic Dermatitis severity according SCORAD test
\<16 mild; \>16\<40 moderate; \>40 severe
Time frame: At 15 days
Number of atopic dermatitis outbreaks
Number of episodes
Time frame: At 5 months
Duration of stable periods (between outbreaks)
Register of days without outbreaks
Time frame: At 5 months
Patient satisfaction assessed by Visual Analog Scales
Validated scale for patients \<5 years
Time frame: At 5 months
Treatment compliance assessed by Morisky-Green test
Adherence / Compliance
Time frame: At 5 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.